{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:31:31Z","timestamp":1772811091887,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,27]],"date-time":"2012-11-27T00:00:00Z","timestamp":1353974400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Drug Investigation"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s40261-012-0042-0","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T18:06:49Z","timestamp":1355940409000},"page":"55-63","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80\u00a0Years: An Interim Analysis of the EXELS Study"],"prefix":"10.1007","volume":"33","author":[{"given":"Jean-Jacques","family":"Kiladjian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Besses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Coll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Birgeg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,27]]},"reference":[{"key":"42_CR1","volume-title":"WHO Classification of Tumours of Haemopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haemopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008.","edition":"4"},{"key":"42_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939430","volume":"32","author":"P Johansson","year":"2006","unstructured":"Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:171\u20133.","journal-title":"Semin Thromb Hemost"},{"key":"42_CR3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajh.21129","volume":"83","author":"X Ma","year":"2008","unstructured":"Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008;83:359\u201362.","journal-title":"Am J Hematol"},{"key":"42_CR4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","volume":"13","author":"C Besses","year":"1999","unstructured":"Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150\u20134.","journal-title":"Leukemia"},{"key":"42_CR5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","volume":"8","author":"S Cortelazzo","year":"1990","unstructured":"Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556\u201362.","journal-title":"J Clin Oncol"},{"key":"42_CR6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132\u20136.","journal-title":"N Engl J Med"},{"key":"42_CR7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","volume":"117","author":"F Passamonti","year":"2004","unstructured":"Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755\u201361.","journal-title":"Am J Med"},{"key":"42_CR8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761\u201370.","journal-title":"J Clin Oncol"},{"key":"42_CR9","unstructured":"European Medicines Agency. Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000480\/WC500056557.pdf . Accessed 7 Feb 2012."},{"key":"42_CR10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","volume":"92","author":"Anagrelide Study Group","year":"1992","unstructured":"Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992;92:69\u201376.","journal-title":"Am J Med"},{"key":"42_CR11","first-page":"520","volume":"89","author":"G Birgegard","year":"2004","unstructured":"Birgegard G, Bjorkholm M, Kutti J, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica. 2004;89:520\u20137.","journal-title":"Haematologica"},{"key":"42_CR12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.leukres.2011.06.030","volume":"35","author":"L Gugliotta","year":"2011","unstructured":"Gugliotta L, Tieghi A, Tortorella G, et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res. 2011;35:1557\u201363.","journal-title":"Leuk Res"},{"key":"42_CR13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33\u201345.","journal-title":"N Engl J Med"},{"key":"42_CR14","unstructured":"Kiladjian JJ, Besses C, Griesshammer M, et al. Management of elderly patients with essential thrombocythemia: an observational study of 471 patients of 80\u00a0years and older included in the EXELS European study [abstract no. 0911]. Haematologica 2011;96(Suppl. 2):379."},{"key":"42_CR15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00043426-199809000-00012","volume":"20","author":"H Lackner","year":"1998","unstructured":"Lackner H, Urban C, Beham-Schmid C, et al. Treatment of children with anagrelide for thrombocythemia. J Pediatr Hematol Oncol. 1998;20:469\u201373.","journal-title":"J Pediatr Hematol Oncol"},{"key":"42_CR16","first-page":"1306","volume":"89","author":"MG Mazzucconi","year":"2004","unstructured":"Mazzucconi MG, Redi R, Bernasconi S, et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica. 2004;89:1306\u201313.","journal-title":"Haematologica"},{"key":"42_CR17","first-page":"834","volume":"8","author":"M Mitura-Lesiuk","year":"2004","unstructured":"Mitura-Lesiuk M, Filiks-Litwin B, Malek U, et al. Diagnostic and therapeutic management of essential thrombocythemia in children [in Polish]. Med Wieku Rozwoj. 2004;8:834\u20138.","journal-title":"Med Wieku Rozwoj"},{"key":"42_CR18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/j.1538-7836.2010.03986.x","volume":"8","author":"MJ Engbers","year":"2010","unstructured":"Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost. 2010;8:2105\u201312.","journal-title":"J Thromb Haemost"},{"key":"42_CR19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2011.08903.x","volume":"156","author":"F Palandri","year":"2012","unstructured":"Palandri F, Polverelli N, Catani L, et al. Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75\u00a0years. Br J Haematol. 2012;156:676\u20139.","journal-title":"Br J Haematol"},{"key":"42_CR20","first-page":"29","volume":"34","author":"S Murphy","year":"1997","unstructured":"Murphy S, Peterson P, Iland H, et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29\u201339.","journal-title":"Semin Hematol"},{"key":"42_CR21","volume-title":"Worldwide prevalence of anaemia 1993\u20132005","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. Worldwide prevalence of anaemia 1993\u20132005. Geneva: WHO; 2008."},{"key":"42_CR22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/ajh.20222","volume":"77","author":"FI Jabr","year":"2004","unstructured":"Jabr FI, Shamseddine A, Taher A. Hydroxyurea-induced hemolytic anemia in a patient with essential thrombocythemia. Am J Hematol. 2004;77:374\u20136.","journal-title":"Am J Hematol"},{"key":"42_CR23","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","volume":"89","author":"A Martinez-Trillos","year":"2010","unstructured":"Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol. 2010;89:1233\u20137.","journal-title":"Ann Hematol"},{"key":"42_CR24","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3324\/haematol.13692","volume":"93","author":"KV Patel","year":"2008","unstructured":"Patel KV. Variability and heritability of hemoglobin concentration: an opportunity to improve understanding of anemia in older adults. Haematologica. 2008;93:1281\u20133.","journal-title":"Haematologica"},{"key":"42_CR25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2257.2004.00637.x","volume":"26","author":"E Penninga","year":"2004","unstructured":"Penninga E, Jensen BA, Hansen PB, et al. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin Lab Haematol. 2004;26:335\u201340.","journal-title":"Clin Lab Haematol"},{"key":"42_CR26","first-page":"215","volume":"89","author":"T Barbui","year":"2004","unstructured":"Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215\u201332.","journal-title":"Haematologica"},{"key":"42_CR27","unstructured":"European Commission. EUROSTAT. http:\/\/epp.eurostat.ec.europa.eu\/portal\/page\/portal\/health\/public_health\/data_public_health\/database . Accessed 2 July 2012."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-012-0042-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0042-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0042-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T13:12:13Z","timestamp":1551186733000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-012-0042-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["42"],"URL":"https:\/\/doi.org\/10.1007\/s40261-012-0042-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,27]]}}}